arGEN-X argen-x.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

arGEN-X (EBR: ARGX) (NASDAQ: ARGX) is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is creating first and best in class antibody therapeutics with highly differentiated target product profiles. Its therapeutic antibody programs, focused on cancer and autoimmune indications, are designed to deliver tangible benefits to patients with these diseases.

arGEN-X (EBR: ARGX) (NASDAQ: ARGX) is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is creating first and best in class antibody therapeutics...Show all

Company (IPO / Went public)

Phone: +31 (0) 10 70 38 441

Fax:

Willemstraat 5

Breda, 4811 AH
Netherlands

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
arGEN-X $121.7M Jul 9, 2014

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related arGEN-X Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 12 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Chimeric human-llama antigens and methods of use Nov 05, 2012 Mar 27, 2018 Patent
Anti c-met antibodies Dec 06, 2013 Feb 06, 2018 Patent
Antibodies to cd70 Jan 24, 2014 Sep 19, 2017 Patent
Antibodies to cd70 Mar 16, 2012 Sep 19, 2017 Patent
Anti c-met antibodies Feb 17, 2015 Jun 27, 2017 Patent
See all 31 patents